109 related articles for article (PubMed ID: 23769558)
1. Hypermethylation of testis derived transcript gene promoter significantly correlates with worse outcomes in glioblastoma patients.
Wang LJ; Bai Y; Bao ZS; Chen Y; Yan ZH; Zhang W; Zhang QG
Chin Med J (Engl); 2013; 126(11):2062-6. PubMed ID: 23769558
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome.
Bai Y; Zhang QG; Wang XH
Eur J Med Res; 2014 Dec; 19(1):66. PubMed ID: 25498217
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.
Mueller W; Nutt CL; Ehrich M; Riemenschneider MJ; von Deimling A; van den Boom D; Louis DN
Oncogene; 2007 Jan; 26(4):583-93. PubMed ID: 16909125
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.
Skiriutė D; Vaitkienė P; Ašmonienė V; Steponaitis G; Deltuva VP; Tamašauskas A
J Neurooncol; 2013 Jul; 113(3):441-9. PubMed ID: 23624749
[TBL] [Abstract][Full Text] [Related]
5. Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines.
Zhang C; Meng W; Wang J; Lu Y; Hu G; Hu L; Ma J
Cell Mol Neurobiol; 2017 Aug; 37(6):1021-1027. PubMed ID: 27757741
[TBL] [Abstract][Full Text] [Related]
6. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
8. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma.
Kim TY; Zhong S; Fields CR; Kim JH; Robertson KD
Cancer Res; 2006 Aug; 66(15):7490-501. PubMed ID: 16885346
[TBL] [Abstract][Full Text] [Related]
9. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
[TBL] [Abstract][Full Text] [Related]
10. Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India.
Nehru GA; Pai R; Samuel P; Chacko AG; Chacko G
Neurol India; 2012; 60(5):481-6. PubMed ID: 23135024
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
Bae SI; Lee HS; Kim SH; Kim WH
Br J Cancer; 2002 Jun; 86(12):1888-92. PubMed ID: 12085181
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
13. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin D1 in human glioblastoma multiforme.
Ghasemi A; Fallah S; Ansari M
Biochem Cell Biol; 2016 Dec; 94(6):569-576. PubMed ID: 27783537
[TBL] [Abstract][Full Text] [Related]
15. [Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].
Frühwald MC; O'Dorisio MS; Smith L; Dai Z; Wright FA; Paulus W; Jürgens H; Plass C
Klin Padiatr; 2001; 213(4):197-203. PubMed ID: 11528554
[TBL] [Abstract][Full Text] [Related]
16. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
18. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
[TBL] [Abstract][Full Text] [Related]
19. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
Neumann O; Kesselmeier M; Geffers R; Pellegrino R; Radlwimmer B; Hoffmann K; Ehemann V; Schemmer P; Schirmacher P; Lorenzo Bermejo J; Longerich T
Hepatology; 2012 Nov; 56(5):1817-27. PubMed ID: 22689435
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
